105 related articles for article (PubMed ID: 15650004)
41. Prevalence of Tropheryma whipplei DNA in patients with various gastrointestinal diseases and in healthy controls.
Amsler L; Bauernfeind P; Nigg C; Maibach RC; Steffen R; Altwegg M
Infection; 2003 Mar; 31(2):81-5. PubMed ID: 12682812
[TBL] [Abstract][Full Text] [Related]
42. False positive PCR detection of Tropheryma whipplei in the saliva of healthy people.
Rolain JM; Fenollar F; Raoult D
BMC Microbiol; 2007 May; 7():48. PubMed ID: 17535423
[TBL] [Abstract][Full Text] [Related]
43. A paradoxical Tropheryma whipplei western blot differentiates patients with whipple disease from asymptomatic carriers.
Fenollar F; Amphoux B; Raoult D
Clin Infect Dis; 2009 Sep; 49(5):717-23. PubMed ID: 19635029
[TBL] [Abstract][Full Text] [Related]
44. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods.
Luna VA; King DS; Gulledge J; Cannons AC; Amuso PT; Cattani J
J Antimicrob Chemother; 2007 Sep; 60(3):555-67. PubMed ID: 17586563
[TBL] [Abstract][Full Text] [Related]
45. The combination of chloroquine and minocycline, a therapeutic option in cerebrospinal infection of Whipple's disease refractory to treatment with ceftriaxone, meropenem and co-trimoxazole.
Feurle GE; Moos V; Schneider T; Fenollar F; Raoult D
J Antimicrob Chemother; 2012 May; 67(5):1295-6. PubMed ID: 22287233
[No Abstract] [Full Text] [Related]
46. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
47. Comment on: evidence of lifetime susceptibility to Tropheryma whipplei in patients with Whipple's disease.
Carlson JA; Schaller J; Sell S
J Antimicrob Chemother; 2011 Nov; 66(11):2681-2. PubMed ID: 21856790
[No Abstract] [Full Text] [Related]
48. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
49. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
50. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.
Landman D; Bratu S; Alam M; Quale J
J Antimicrob Chemother; 2005 Jun; 55(6):954-7. PubMed ID: 15883174
[TBL] [Abstract][Full Text] [Related]
51. Tropheryma whipplei natural resistance to trimethoprim and sulphonamides in vitro.
Fenollar F; Perreal C; Raoult D
Int J Antimicrob Agents; 2014 Apr; 43(4):388-90. PubMed ID: 24613421
[No Abstract] [Full Text] [Related]
52. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
53. A selective enumeration medium for Carnobacterium maltaromaticum.
Edima HC; Cailliez-Grimal C; Revol-Junelles AM; Tonti L; Linder M; Millière JB
J Microbiol Methods; 2007 Mar; 68(3):516-21. PubMed ID: 17145089
[TBL] [Abstract][Full Text] [Related]
54. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
Seifert H; Dowzicky MJ
Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
[TBL] [Abstract][Full Text] [Related]
55. Polyamine effects on antibiotic susceptibility in bacteria.
Kwon DH; Lu CD
Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056
[TBL] [Abstract][Full Text] [Related]
56. Occurrence of antimicrobial resistance in bacteria from diagnostic samples from dogs.
Pedersen K; Pedersen K; Jensen H; Finster K; Jensen VF; Heuer OE
J Antimicrob Chemother; 2007 Oct; 60(4):775-81. PubMed ID: 17644533
[TBL] [Abstract][Full Text] [Related]
57. Comment on: therapy for Whipple's disease.
Bakkali N; Fenollar F; Rolain JM; Raoult D
J Antimicrob Chemother; 2008 Apr; 61(4):968-9; author reply 969-70. PubMed ID: 18252691
[No Abstract] [Full Text] [Related]
58. Frequency of isolation and antimicrobial susceptibility of bacteria isolated from bloodstream infections at Children's Medical Center, Tehran, Iran, 1996-2000.
Mamishi S; Pourakbari B; Ashtiani MH; Hashemi FB
Int J Antimicrob Agents; 2005 Nov; 26(5):373-9. PubMed ID: 16213124
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
Behra-Miellet J; Dubreuil L; Calvet L
Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
[TBL] [Abstract][Full Text] [Related]
60. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
